Other News To Note
Tuesday, April 17, 2012
Nascent Biologics Inc., of Somerset, N.J., inked a deal for Catalent Pharma Solutions, of San Diego, to engineer a cell line expressing Nascent's Pritumumab antibody and subsequently produce purified monoclonal antibodies to support Nascent's Phase I/II trials in brain cancers such as astrocytomas and glioblastomas.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.